Catalent, Inc. (NYSE:CTLT) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. raised its position in Catalent, Inc. (NYSE:CTLT) by 3.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 405,318 shares of the company’s stock after acquiring an additional 14,373 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Catalent were worth $24,550,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Catalent by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock worth $1,151,872,000 after purchasing an additional 218,682 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after purchasing an additional 2,299,784 shares during the period. Alpine Associates Management Inc. boosted its holdings in Catalent by 3.8% during the second quarter. Alpine Associates Management Inc. now owns 2,061,251 shares of the company’s stock worth $115,904,000 after buying an additional 75,700 shares in the last quarter. Bank of New York Mellon Corp grew its position in Catalent by 14.9% during the second quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company’s stock worth $108,559,000 after buying an additional 250,999 shares during the period. Finally, Marshall Wace LLP increased its holdings in Catalent by 5.1% in the second quarter. Marshall Wace LLP now owns 1,792,951 shares of the company’s stock valued at $100,818,000 after buying an additional 86,533 shares in the last quarter.

Catalent Stock Performance

Catalent stock opened at $59.10 on Friday. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.20. The company has a market capitalization of $10.73 billion, a price-to-earnings ratio of -26.15, a PEG ratio of 2.35 and a beta of 1.16. The stock has a fifty day moving average of $59.84 and a two-hundred day moving average of $58.20. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.10) EPS. On average, analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Insider Activity

In other news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 over the last 90 days. Insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

CTLT has been the topic of several research analyst reports. StockNews.com raised Catalent from a “sell” rating to a “hold” rating in a research note on Thursday. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Eight investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Catalent currently has an average rating of “Hold” and an average target price of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.